silvia funghini

silvia funghini

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
Margherita RuoppoloMargherita Ruoppolo
Margherita Ruoppolo
SMSabrina Malvagia
Sabrina Malvagia
SBSara Boenzi
Sara Boenzi
CCcarla carducci
carla carducci
CDCarlo Dionisi-Vici
Carlo Dionisi-Vici
AUAnna Paola Uccheddu
Anna Paola Uccheddu
Newborn screening (NBS) for inborn errors of metabolism is one of the most advanced tools for secondary prevention in medicine, as it allows early diagnosis and prompt treatment initiation. The expanded newborn screening was introduced in Italy between 2016 and 2017 (Law 167/2016; DM 13 October 2016; DPCM 12-1-2017). A total of 1,586,578 infants born in Italy were screened between January 2017 and December 2020. For this survey, we collected data from 15 Italian screening laboratories, focusing on the metabolic disorders identified by tandem mass spectrometry (MS/MS) based analysis between January 2019 and December 2020. Aminoacidemias were the most common inborn errors in Italy, and an equal percentage was observed in detecting organic acidemias and mitochondrial fatty acids beta-oxidation defects. Second-tier tests are widely used in most laboratories to reduce false positives. For example, second-tier tests for methylmalonic acid and homocysteine considerably improved the screening of CblC without increasing unnecessary recalls. Finally, the newborn screening allowed us to identify conditions that are mainly secondary to a maternal deficiency. We describe the goals reached since the introduction of the screening in Italy by exchanging knowledge and experiences among the laboratories.

16 July 2014 in Orphanet Journal of Rare Diseases
Verified
Journal Article
Open access
PDF file
CCCatia Cavicchi
Catia Cavicchi
MDMaria Alice Donati
Maria Alice Donati
RPRossella Parini
Rossella Parini
MRMiriam Rigoldi
Miriam Rigoldi
MBMauro Bernardi
Mauro Bernardi
AMAmelia Morrone
Amelia Morrone
X-linked Ornithine Transcarbamylase deficiency (OTCD) is often unrecognized in adults, as clinical manifestations are non-specific, often episodic and unmasked by precipitants, and laboratory findings can be normal outside the acute phase. It may thus be associated with significant mortality if not promptly recognized and treated. The aim of this study was to provide clues for recognition of OTCD in adults and analyze the environmental factors that, interacting with OTC gene mutations, might have triggered acute clinical manifestations.

14 February 2013 in Orphanet Journal of Rare Diseases
Verified
Journal Article
Open access
PDF file
LFLorenzo Ferri
Lorenzo Ferri
MDMaria Alice Donati
Maria Alice Donati
SFsilvia funghini
silvia funghini
SMSabrina Malvagia
Sabrina Malvagia
SCSerena Catarzi
Serena Catarzi
AMAmelia Morrone
Amelia Morrone
Background: Barth syndrome (BS) is an X-linked infantile-onset cardioskeletal disease characterized by cardiomyopathy, hypotonia, growth delay, neutropenia and 3-methylglutaconic aciduria. It is caused by mutations in the TAZ gene encoding tafazzin, a protein involved in the metabolism of cardiolipin, a mitochondrial-specific phospholipid involved in mitochondrial energy production. Methods: Clinical, biochemical and molecular characterization of a group of six male patients suspected of having BS. Three patients presented early with severe metabolic decompensation including respiratory distress, oxygen desaturation and cardiomyopathy and died within the first year of life. The remaining three patients had cardiomyopathy, hypotonia and growth delay and are still alive. Cardiomyopathy was detected during pregnancy through a routine check-up in one patient. All patients exhibited 3-methylglutaconic aciduria and neutropenia, when tested and five of them also had lactic acidosis. Results: We confirmed the diagnosis of BS with sequence analysis of the TAZ gene, and found five new mutations, c.641A>G p.His214Arg, c.284dupG (p.Thr96Aspfs*37), c.678_691del14 (p.Tyr227Trpfs*79), g.8009_16445del8437 and g.[9777_9814del38; 9911-?_14402del] and the known nonsense mutation c.367C>T (p.Arg123Term). The two gross rearrangements ablated TAZ exons 6 to 11 and probably originated by non-allelic homologous recombination and by Serial Replication Slippage (SRS), respectively. The identification of the breakpoints boundaries of the gross deletions allowed the direct detection of heterozygosity in carrier females. Conclusions: Lactic acidosis associated with 3-methylglutaconic aciduria is highly suggestive of BS, whilst the severity of the metabolic decompensation at disease onset should be considered for prognostic purposes. Mutation analysis of the TAZ gene is necessary for confirming the clinical and biochemical diagnosis in probands in order to identify heterozygous carriers and supporting prenatal diagnosis and genetic counseling.

1 February 2015 in Clinica Chimica Acta
Verified
Journal Article
Closed access
FVFabio Villanelli
Fabio Villanelli
EGElisa Giocaliere
Elisa Giocaliere
SMSabrina Malvagia
Sabrina Malvagia
ARAnna Rosati
Anna Rosati
GFGiulia Forni
Giulia Forni
GMGiancarlo La Marca
Giancarlo La Marca

18 November 2013 in Clinical Genetics
Verified
Journal Article
Closed access
PDF file
LFL. Ferri
L. Ferri
SFsilvia funghini
silvia funghini
AFAntonella Fioravanti
Antonella Fioravanti
EBE.G. Biondi
E.G. Biondi
GMGiancarlo La Marca
Giancarlo La Marca
AMAmelia Morrone
Amelia Morrone

1 May 2015 in Clinica Chimica Acta
Verified
Journal Article
Closed access
RTRodolfo Tonin
Rodolfo Tonin
ACAnna Caciotti
Anna Caciotti
SFsilvia funghini
silvia funghini
GMGiancarlo La Marca
Giancarlo La Marca
EPElisabetta Pasquini
Elisabetta Pasquini
AMAmelia Morrone
Amelia Morrone